Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Zongertinib |
Synonyms | |
Therapy Description |
BI 1810631 is an ERBB2 (HER2) selective inhibitor with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS9143, PMID: 36528522). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Zongertinib | BI-1810631|BI1810631|BI 1810631 | HER2 Inhibitor 42 | Zongertinib is an ERBB2 (HER2) selective inhibitor with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS9143, PMID: 36528522). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06581432 | Phase II | Zongertinib | Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Recruiting | USA | ESP | CAN | AUS | 3 |
NCT06151574 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Zongertinib | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Recruiting | USA | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | ARG | 6 |
NCT04886804 | Phase I | Zongertinib | A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 6 |